Advanced breast cancer: investigational role of gemcitabine

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
J Carmichael, J Walling

Abstract

There have been many recent advances in the treatment of advanced breast cancer including the introduction of novel drugs and the development of high-dose chemotherapy with peripheral blood stem cell transplantation (PBSCT). These innovations may offer significant hope for improvement in the treatment of breast cancer in the near future. Gemcitabine is a nucleoside analogue with significant antitumour activity in many human solid tumours. Conflicting results have been observed from studies evaluating gemcitabine in advanced breast cancer. Efficacy data for single-agent gemcitabine range from 25 to 46% depending on starting dose and whether patients have previously received chemotherapy for metastatic disease (as well as adjuvant use). Gemcitabine is extremely well tolerated, even in heavily pre-treated patients, and is easy to administer on an outpatient basis to both chemo-naive and previously treated patients. The most common toxicity is mild myelosuppression. Gemcitabine causes minimal nausea and vomiting, and significant hair loss is extremely uncommon. Combination chemotherapy studies with anthracyclines are underway and significant activity has been observed in combination with both doxorubicin and epirubicin. In view of ...Continue Reading

References

Jan 1, 1992·Oncology·W R BezwodaS Ariad
Dec 18, 1991·Journal of the National Cancer Institute·F A HolmesG N Hortobagyi
Feb 1, 1989·European Journal of Cancer & Clinical Oncology·W G Jones
Nov 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J CarmichaelA L Harris
Oct 19, 1994·Journal of the National Cancer Institute·B LundJ P Neijt
Aug 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R P AbrattT A Rugg
Sep 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H AndersonH H Hansen
Dec 1, 1995·Anti-cancer Drugs·K Possinger
Mar 12, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D PectasidesA Athanassiou
Nov 3, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A SchneeweissG Bastert
Oct 19, 2006·The Breast : Official Journal of the European Society of Mastology·Mario CamponePierre Pouillart

❮ Previous
Next ❯

Citations

Nov 24, 2004·Oncology·D MavroudisUNKNOWN Breast Cancer Study Group of the Hellenic Oncology Research Group (HORG)
Jul 2, 2014·Bioelectrochemistry·Rafael M BuoroAna Maria Oliveira-Brett
Jan 20, 2016·Archives of Pharmacal Research·Dae Hwan ShinJin-Seok Kim
Sep 3, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Ulrich KeilholzEckhard Thiel
Jul 9, 2005·Expert Review of Anticancer Therapy·Volker Heinemann

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.